Oncologie

Vinorelbine medac (Soft Capsules)

Description du produit

The cytostatic drug vinorelbine is a vinca alkaloid whose cytotoxic effect is based on binding to the microtubule apparatus. The binding promotes the depolymerisation of tubulin and at the same time disturbs the polymerisation, which is why microtubules can no longer be formed. The spindle apparatus is no longer built properly and mitosis is inhibited. The substance blocks the cell cycle in the G2 or M phase, whereby the cells eventually die. In addition, vinca alkaloids block DNA and RNA synthesis.

Dénomination Commune Internationale (DCI)

Vinorelbine tartrate

Mode d'action

Vinorelbine is an antineoplastic substance from the group of vinka alkaloids. At the molecular level, vinorelbine acts on the tubulin-microtubule system of the cell. Vinorelbine prevents the polymerisation of tubulin, preferentially attaching to mitotic microtubules. Axonal microtubules are only affected at high drug concentrations. The spiralisation of tubulin induced by vinorelbine is less pronounced than with vincristine. Vinorelbine leads to blockage of mitosis in G2/M phase, with cell death occurring in interphase or subsequent mitotic phase. Vinorelbine differs from the other representatives of the vinka alkaloids by a structurally altered catharantine portion in the molecule.

Indication

  • Advanced breast cancer
  • Non-small cell lung cancer

Dosage

Soft capsules:

  • 20 mg
  • 30 mg
  • 80 mg

Not all pack sizes may be marketed.

Matériaux

Abbreviated product information

Ouvrir le lien External Link